BRAF is therefore considered to be an oncogenic driver in colorectal tumours,7 although the molecular, morphological, epidemiological and clinical characteristics of the serrated polyps initiated by BRAF differ from the polyps of the ‘classic’ adenoma–carcinoma sequence driven by mutations in the adenomatous polyposis coli (APC) gene.8 This evidence concerns the gene BRAF and colorectal neoplasm.